Somatostatin analogues have no role in the treatment of advanced differentiated thyroid cancer

O. Alhamarneh, J. Murphy, S. L. Atkin, R. J.A. England

Research output: Contribution to journalArticle

Abstract

Somatostatins are neuropeptides that have a downregulatory effect on various physiological processes. Their use in the management of certain endocrine tumours is well recognized. Their use in thyroid cancer is not established, although there is some evidence to suggest that they have a role in advanced metastatic disease. We report a case of a patient with advanced metastatic follicular thyroid cancer which demonstrated strong octreotide uptake with reduced avidity for I131. Treatment with the somatostatin analogue octreotide, however, failed to achieve a significant response. We feel this case is important as it suggests that although octreotide provides a useful further imaging modality in differentiated thyroid cancer, it has no therapeutic role.

Original languageEnglish
Pages (from-to)653-654
Number of pages2
JournalJournal of Laryngology and Otology
Volume118
Issue number8
DOIs
Publication statusPublished - 1 Aug 2004

Keywords

  • Somatostatin
  • Thyroid Neoplasms

ASJC Scopus subject areas

  • Otorhinolaryngology

Fingerprint Dive into the research topics of 'Somatostatin analogues have no role in the treatment of advanced differentiated thyroid cancer'. Together they form a unique fingerprint.

  • Cite this